Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A detailed comparison of how the FDA and EMA evaluated, approved, and regulate liraglutide (Victoza, Saxenda), covering label differences, post-market surveillance, and safety signals.
Read clinical reviewA clinical review of liraglutide safety signals reported through the FDA Adverse Event Reporting System (FAERS), including pancreatitis, gallbladder events, thyroid concerns, and acute kidney injury.
Read clinical reviewFull FDA approval history for liraglutide (Victoza, Saxenda), covering every indication, label expansion, boxed warning, post-market safety update, and generic entry from 2010 through 2025.
Read clinical reviewA complete clinical and regulatory guide to liraglutide's patent field, FDA approval history, prescribing label, and post-market safety record, reviewed by the HealthRX.com medical team.
Read clinical reviewA clinical review of liraglutide's regulatory history, current FDA label, generic pipeline status, and next-generation GLP-1 receptor agonists positioned to follow it.
Read clinical review